ArticleMolecular and cellular biochemistry2026
Growth differentiation factor 11 attenuates doxorubicin-induced cardiotoxicity by inhibiting myocardial pyroptosis and oxidative stress.
Article in Molecular and cellular biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
11 authors.
Funding
Abstract
Doxorubicin (DOX) is limited in clinical application because of its cardiotoxicity. One of the key elements of DOX-induced cardiotoxicity is pyroptosis, a kind of programmed cell death brought on by immunity and followed by inflammatory response. Growth differentiation factor (GDF) 11 plays an significant role in oxidative stress and inflammation. The purpose of this work was to determine if GDF11 inhibits oxidative stress and pyroptosis in order to lessen the cardiotoxicity caused by DOX. SD rats were used to establish an in vivo model by intraperitoneal injection of DOX and induction of GDF11 overexpression in the heart using adeno-associated virus type 9 (AAV9). Human cardiomyocytes (AC16) were used to create the in-vitro model. By measuring the degree of cardiac function, cardiac fibrosis, inflammation, and oxidative stress; using transmission electron microscopy to examine the rat heart's microstructure; analyzing the expression of proteins of pyroptosis and oxidative stress-associated nuclear factor E2-related factor (Nrf-2)/heme oxygenase-1 (HO-1) pathway, the protective mechanism of GDF11 against DOX-induced cardiotoxicity was explored. GDF11 decreased the expression level of cardiac function, oxidative stress and inflammation-related indexes, attenuated the degree of DOX-induced cardiac fibrosis, and had some protective effects against damage to the rat heart's microstructures. Besides, GDF11 decreased the level of oxidative stress and restored the levels of anti-oxidative stress and other proteins, including Nrf-2, while also reduced the expression of DOX-induced pyroptosis-related proteins. GDF11 attenuates DOX-induced cardiotoxicity by inhibiting pyroptosis and oxidative stress, which provides new ideas for clinical improvement of DOX-induced myocardial injury.
Indexed as
Identifiers
41136737What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.